Form 4: Iovance Biotherapeutics Executive Graf Finckenstein Reports Stock Transactions
SEC Form 4 Filing
Friedrich Graf Finckenstein, Chief Medical Officer of Iovance Biotherapeutics, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On October 14, 2024, Friedrich Graf Finckenstein, the Chief Medical Officer of Iovance Biotherapeutics, had 2,813 restricted stock units (RSUs) vest.
- The company withheld 1,428 shares to satisfy tax withholding requirements at a price of $9.77 per share.
- Following these transactions, Graf Finckenstein directly owns 60,727 shares of Iovance Biotherapeutics common stock.
- He also holds 2,813 remaining restricted stock units that will vest in equal quarterly installments.
Sentiment
Score: 5
Explanation: This is a routine disclosure of stock transactions by a company executive, and doesn't inherently indicate positive or negative sentiment. It's a neutral event.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Key Dates
| Date | Description |
|---|---|
| January 14, 2022 | Date of grant for the reported Restricted Stock Units |
| October 14, 2024 | Date of RSU vesting and tax withholding. |
| October 16, 2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.